<p><strong> </strong><strong>In mCRPC patients with disease progression following treatment with an ARPI, clinicians should offer docetaxel. <em>(Strong Recommendation; Evidence Level: Grade B)</em></strong></p>
Discussion
Discussion
<p>Docetaxel (typically in combination with 10 mg of prednisone/day) is an effective option in both mCRPC and mHSPC and should be considered as standard first-line chemotherapy in the setting of mCRPC based on a randomized, multicenter, active-controlled trial (TAX 327),<sup>22</sup> which demonstrated a statistically significant OS advantage over mitoxantrone, with a median survival of 18.9 months versus 16.5 months (HR=0.761; 95% CI: 0.619 to 0.936). The palliative data from this study is compelling demonstrating significant pain reduction and improvement in QOL.<sup>124</sup></p>